Table 1.
Patient and clinical characteristics for both cohorts of patients. NCDB—National Cancer Database; N—sample size; BMI—body mass index; NAC—neoadjuvant chemotherapy; IQR—interquartile range; mos—months.
| Variable | Entire Cohort | NCDB | Yale Cohort |
|---|---|---|---|
| N | 146 | 123 | 23 |
| Male sex | 118 (79.3%) | 90 (73.2%) | 18 (79.2%) |
| Age | 68.8 [IQR 64.2, 73.2] | 68.9 [IQR 65.4, 72.5] | 68.4 [IQR 63.0, 75.3] |
| Race | |||
| White | 132 (90.4%) | 113 (91.5%) | 19 (86.9%) |
| Black | 12 (8.2%) | 8 (6.9%) | 4 (13.1%) |
| Asian | 1 (0.7%) | 1 (0.8%) | 0% |
| Other | 1 (0.7%) | 1 (0.8%) | 0% |
| BMI | N/A | N/A | 26.7 |
| Practice type | |||
| Academic | 123 (87.0%) | 100 (81.3%) | 23 (100.0%) |
| Private | 1 (0.6%) | 1 (0.8%) | 0 (0%) |
| Mixed | 22 (17.5%) | 22 (17.9%) | 0 (0%) |
| cT | |||
| 0 | 1 (0.8%) | 1 (1.0%) | 0 (0%) |
| 1 | 31 (21.0%) | 26 (21.1%) | 5 (20.0%) |
| 2 | 71 (48.3%) | 61 (49.5) | 10 (47.2%) |
| 3 | 25 (17.4%) | 20 (16.2%) | 5 (20.0%) |
| 4 | 18 (12.5%) | 15 (12.2%) | 3 (12.0%) |
| cN+ | 13 (8.9%) | 11 (8.7%) | 2 (7.3%) |
| Treatment | |||
| Radical cystectomy | 89 (61.0%) | 75 (61.0%) | 14 (60.8%) |
| Observation | 12 (8.0%) | 10 (8.1%) | 2 (8.8%) |
| Primary radiation | 45 (31.0%) | 38 (30.9%) | 7 (30.4%) |
| NAC | 25 (28.0%) | 16 (21.3%) | 9 (64.2%) |
| Agent | |||
| Chemotherapy | N/A | N/A | |
| Cisplatin-based | 21 (92.3%) | ||
| Other | |||
| Enfortumab vedotin | 2 (7.7%) | ||
| pT | |||
| 0 | 18 (12.4%) | 14 (11.2%) | 4 (15.3%) |
| 1 | 2 (1.4%) | 2 (1.6%) | 0 (0%) |
| 2 | 17 (11.6%) | 15 (12.5%) | 2 (7.7%) |
| 3 | 53 (36.3%) | 40 (32.5%) | 13 (61.5%) |
| 4 | 56 (38.3%) | 52 (42.2%) | 4 (15.5%) |
| pN | |||
| pN0 | 73 (50.0%) | 55 (44.7%) | 17 (76.9%) |
| pN+ | 42 (28.7%) | 37 (30.0%) | 5 (23.1%) |
| pNx | 31 (21.3%) | 31 (25.3%) | 0 (0%) |
| Median survival (mos) | 28 [IQR 7.5, 50.3] | 23 [IQR 8.4, 46.3] | 36 [IQR 4.3, 68.1] |